Summary：**Top 3 ASX Small-Cap Shares to Buy Now: Expert Morgans' Picks Revealed**The Australian Securities E

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Top 3 ASX Small-Cap Shares to Buy Now: Expert Morgans' Picks Revealed**

The Australian Securities Exchange (ASX) small-cap sector has been underwhelming in 2026, with many investors left searching for opportunities amidst the lackluster performance. However, investment firm Morgans has identified three small-cap shares that it believes are poised for growth, presenting a compelling buying opportunity for investors.

**Key Developments**

Morgans has highlighted three ASX small-cap shares that are demonstrating strong potential for future growth. The first is **Adore Beauty Group Ltd (ASX:ABY)**, which has been gaining traction in the e-commerce space. The second is **Cynata Therapeutics Ltd (ASX:CYP)**, a biotechnology company that has made significant strides in developing innovative cell therapy products. The third is **Optiscan Imaging Ltd (ASX:OIL)**, a medical technology company that has been making waves with its advanced microscopy solutions. Each of these companies has demonstrated unique strengths and growth prospects, making them attractive to investors.

**Industry Analysis**

The e-commerce, biotechnology, and medical technology sectors are all experiencing significant growth, driven by technological advancements and changing consumer behaviors. Adore Beauty's strong online presence positions it well to capitalize on the ongoing shift to e-commerce. Cynata Therapeutics is benefiting from the growing demand for innovative cell therapies, while Optiscan Imaging is poised to leverage the increasing adoption of advanced microscopy solutions in the medical field. Morgans' picks are well-placed to take advantage of these trends.

**Future Outlook**

Looking ahead, Morgans expects these three small-cap shares to continue their growth trajectory. Adore Beauty is likely to expand its market share, driven by its strong brand and online presence. Cynata Therapeutics is expected to make significant progress in its clinical trials, potentially leading to increased investor confidence. Optiscan Imaging is poised to benefit from the growing demand for its microscopy solutions, driven by the increasing need for advanced medical technologies.

**Conclusion**

In conclusion, Morgans' picks offer investors a compelling opportunity to tap into the growth potential of the ASX small-cap sector. With Adore Beauty, Cynata Therapeutics, and Optiscan Imaging demonstrating strong prospects for future growth, investors would be wise to consider these shares for their portfolios. As the ASX small-cap sector continues to evolve, it is likely that these companies will play a key role in shaping the market's future.